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Oxidative stress could be involved in the pathophysiology of schizophrenia, a major psychiatric disorder. Glutathione
(GSH), a redox regulator, is decreased in patients’ cerebrospinal fluid and prefrontal cortex. The gene of the key GSH-
synthesizing enzyme, glutamate cysteine ligase modifier (GCLM) subunit, is strongly associated with schizophrenia in
two case-control studies and in one family study. GCLM gene expression is decreased in patients’ fibroblasts. Thus, GSH
metabolism dysfunction is proposed as one of the vulnerability factors for schizophrenia.
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Schizophrenia (MIM 181500) is a major and frequent
chronic psychiatric disorder with a strong genetic com-
ponent.1,2 Converging evidence points to the involvement
of oxidative stress3–7 and N-methyl D-aspartate (NMDA)–
receptor hypofunction8,9 in the pathophysiology of the
disease. As a main cellular nonprotein antioxidant and
redox regulator,10 glutathione (GSH) plays a major role in
protecting nervous tissue against reactive oxygen species11
and in modulating redox-sensitive sites, including NMDA
receptors (NMDA-R).12,13 It was shown elsewhere that the
GSH levels were decreased in patients’ cerebrospinal fluid
(27%), in medial prefrontal cortex in vivo (52%),14,15
and in striatum postmortem tissue.16 GSH-deficient mod-
els reveal morphological, electrophysiological, and behav-
ioral anomalies similar to those observed in patients.17–21
Here, we present strong evidence for an association be-
tween schizophrenia and the gene of the key GSH-syn-
thesizing enzyme, glutamate cysteine ligase modifier
(GCLM) subunit. The functional role of the GCLM gene
variance in schizophrenia is supported by its low expres-
sion in patients’ fibroblasts and by the decreased stimu-
lation of the enzyme activity when challenged by an ox-
idative stress.22 These findings are consistent with the
concept that an abnormal GSH metabolism is a risk factor
for schizophrenia.
To identify candidate gene(s) responsible for the low
level of GSH observed in patients with schizophrenia, we
studied steady-state levels of mRNA for 14 genes (data not
shown) involved in GSH metabolism (fig. 1). Since GSH
is ubiquitously present in cells, gene expression was stud-
ied in cultured skin fibroblasts. Two enzymes are respon-
sible for GSH synthesis: glutamate cysteine ligase (GCL),
also known as g-glutamyl cysteine synthetase (Enzyme
Commission number 6.3.2.2), and glutathione synthetase
(GSS [Enzyme Commission number 6.3.2.3]).10 GCL, the
first and rate-limiting enzyme,10 is composed of two sub-
units—GCL modifier (GCLM [light: 27.7 kDa])23 and GCL
catalytic subunit (GCLC [heavy: 73 kDa])24—each encoded
by separate genes.25 The specific mRNA steady-state levels
were measured in fibroblasts obtained from 32 patients
and 53 controls from a Swiss population (table 1). The
subjects were recruited with fully informed written con-
sent and guidelines for ethical treatment given by the Uni-
versity of Lausanne. All subjects were assessed using the
Diagnostic Interview for Genetic Studies (DIGS) developed
by the National Institute of Mental Health (NIMH).27 Ad-
ditional measures of psychopathology of patients in-
cluded the Positive and Negative Syndrome Scale (PANSS),
which assessed the presence of symptoms within the same
week as the blood collection and skin biopsy. Specific
mRNA steady-state levels were measured in cultured skin
fibroblasts grown for three passages, with the use of
TaqMan chemistry and ABI Prism 7000 sequence detec-
tion system. cDNA corresponding to 10 ng of reverse-tran-
scribed total RNA was amplified using TaqMan gene ex-
pression assays (Hs00155249 m1, Hs00157694 m1, and
Hs00609286 m1) at the following amplification condi-
tion: 1 cycle for 2 min at 50C, 1 cycle for 10 min at 95C,
and 50 cycles for 15 s at 95C, followed by 1 min at 60C.
Human glyceraldehyde-3-phosphate dehydrogenase (Ap-
plied Biosystem 4333764F) was used as endogenous
control.
Case-control comparisons showed significant differ-
ences in GCLM ( ; ) and GSS ( ;tp 1.989 Pp .037 tp 1.997
) mRNA levels between patients and control sub-Pp .030
jects, without effect from sex or age. For the GCLC mRNA,
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Figure 1. GSH metabolic pathway. The genes for which expression was studied in fibroblast cultures from skin biopsies are highlighted.
Black indicates no difference between controls and patients, and red indicates lower expression in patients compared with controls.
These genes code for the enzymes highlighted in yellow. Substrates and products are highlighted in purple. Genes not directly involved
in GSH metabolism but included in the expression study: Nrf1, Nrf2, and Nrf3 p NF-E2–related transcription factors 1, 2, and 3,
respectively; xCT and 4F2p genes encoding proteins involved in cystine/glutamate exchange; and MRP1p multidrug resistance protein
1. ADPp adenosine diphospate; GSSGp glutathione disulfide; RSHp reduced thiols; RSp disulfide; N-AC-CYS-Xp N-acetyl-cysteine
conjugate; Pi p inorganic phosphate.
Table 1. Demographic Characteristics of the Samples
Used in Gene Expression and Association Studies
Study and
Population N
Agea
(years) Sexb Diagnostic Tool
Expression study:
Switzerland:
Patient 32 35.510.5 3.0 DSM-IV26/DIGS27
Control 53 37.213.4 .9 DIGS
Association study:
Switzerland:
Patient 40 35.911.5 3.5 DSM-IV/DIGS
Control 31 37.713.31 1.6 DIGS
Denmark:
Patient 349 38.812.1 1.5 ICD-10c
Control 348 40.210.5 1.5 …
a Expressed as the mean and range.
b Ratio of males to females.
c International Classification of Diseases, 10th Revision.
a trend toward a decrease could be observed ( ;tp 2.000
) in patients.Pp .064
We tested, therefore, whether the reduced GCLM and
GSS mRNA levels observed in patients with schizophrenia
could be due to a primary defect. We studied eight SNPs
in the GCLM gene and nine SNPs in the GSS gene for
possible association with schizophrenia (fig. 2). Sixteen
SNPs were chosen from a group of 60 SNPs selected from
publicly available databases (SNP Consortium and dbSNP)
on the basis of the estimated level of polymorphism in
our population. One SNP (ss60197536) at the GCLM 5′
end, described by Nakamura et al.,28 is being submitted to
dbSNP. The dbSNP-annotated SNP numbers and their po-
sitions in each gene are shown in figure 2. Genotyping
was performed with DNA extracted from peripheral blood
by the use of either Sequenom technology29 or sequenc-
ing. The list of specific primers is shown in table 2.
A pilot association study was performed with a relatively
small sample (40 patients and 31 controls from a Swiss
population) (fig. 2). Most, although not all, of the subjects
from the Swiss population were used in both gene ex-
pression and association studies. The details about subject
groups are given in the tables: demographic data in table
1, genotype and allele frequencies for each SNP in table
3, and the allelic frequencies compared with those known
for other populations in table 4. All SNPs were in Hardy-
588 The American Journal of Human Genetics Volume 79 September 2006 www.ajhg.org
Figure 2. Map of GCLM and GSS genomic structures, with the positions of SNP markers and results of two case-control studies. Tables
show P values for each SNP in case-control studies of subjects from two independent populations, from Switzerland and Denmark. Values
in italics indicate a significant difference, and the value in bold italics indicates a significant difference after correction for multiple
testing.
Table 2. Primers Used in Genotyping
Studies
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3. Genotype and Allele Frequencies
for Each SNP Studied in Two Populations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Weinberg equilibrium (HWE) in both subject groups (data
not shown). No association was observed with the GSS
gene. Two GCLM markers, rs2301022 in intron 1 and
rs3170633 at the 3′ end, had P values that were low, but
not significant after correction for multiple testing. How-
ever, these data suggested that a functional region in
GCLM may be associated with schizophrenia. Conse-
quently, we proceeded with a second case-control study
of a larger sample from an independent population.
The second study included 349 patients with schizo-
phrenia from the Danish Psychiatric Biobank and 348 un-
related anonymous blood donors serving as unaffected
control subjects (table 1). Both control and affected groups
were tested for HWE. Whereas the control group was in
equilibrium for all markers, the SNP rs2301022 showed a
deviation from HWE ( ) in patients. This SNP alsoPp .026
showed an association in our Swiss population. Genotype
frequency analysis confirmed a strong association of SNP
rs2301022 ( , 2 df; ) after correction for2x p 13.2 Pp .023
multiple testing (fig. 2). Thus, the deviation from HWE in
patients but not in controls must be viewed as additional
evidence of association. Here again, no association with
GSS SNPs was found; thus, we excluded this gene from
further studies.
Our results showed that rs2301022 is strongly associated
with schizophrenia. This marker is localized between
markers rs718875 and ss60197536, which showed weaker
association with this disease in one of two populations
that we studied (fig. 2). This fact suggests that there is a
functional variant associated with the disease in the prox-
imity of these three markers. SNP ss60197536 is 343 bp
upstream of the transcription initiation site, and rs718875
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Table 4. Frequencies of the Rare Allele in
Swiss and Danish Populations Compared
with Reported Frequencies in Other White
Populations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3. Genotype distribution of the two most common SNPs
at the GCLM gene in the controls and patients sampled from a
Danish population. The graph shows a dominance of the G allele
for both markers.
Table 5. Diplotype Analysis of the SNP Patterns
Associated with Schizophrenia
Genotype Pattern Frequency
ORrs718875 rs2301022 ss60197536 Patients Controls
CC GG TT .035 .009 4.17
TC GG TT .006 .014 .4
TT GG CC .263 .282 .91
TT GG TC .041 .009 4.89
TT AG TC .05 .035 1.46
TT AG CC .339 .3 1.2
TC GG TC .137 .138 .99
TT AA CC .044 .121 .33
TC AG TC .067 .078 .85
Five rare patterns .018 .014 1.22
NOTE.— , 9 df; . Cells highlighted in bold show2x p 30.40 Pp .000375
significantly different values.
is localized, like rs2301022, in intron 1. We analyzed dif-
ferent genotype pattern classes for these three markers
(ss60197536, rs2301022, and rs718875) in a region of
∼3,000 bp that includes GCLM exon 1. We identified 14
different genotype patterns (table 5), among which 2 were
specifically present in affected individuals. Nine patterns
of these three SNPs showed different frequencies between
patients and unaffected controls, with and2x p 30.39
. Two particular combinations, TT/GG/TC andPp .004
CC/GG/TT, had odds ratios (ORs) of 4.89 and 4.17,
respectively.
At present, we cannot completely exclude the possibility
of a second functionally associated region in the vicinity
of SNP rs3170633. The association test for this SNP showed
low P values in both populations ( ) (fig. 2). How-Pp .009
ever, these values are not significant after correction for
multiple testing.
Genotype frequency distribution in the Danish popu-
lation suggests a dominant mode of transmission for the
two SNPs of interest (rs2301022 and rs3170633), with the
G allele dominant in each of them (fig. 3). For rs2301022,
genotypes AA, AG, and GG show respective ORs of 0.37,
1.22, and 1.12. Thus, we pooled AG and GG genotypes,
since both are associated with disease, to approximately
the same degree. The corresponding OR for disease then
was 2.72 ( ). For rs3170633, which showedPp .0005
weaker association, ( ).ORp 1.77 Pp .002
Thus, case-control studies of two independent popula-
tions provided strong evidence of an association of the
GCLM gene and schizophrenia. These data were supported
with an additional linkage study of the families from the
NIMH cohort, shown in table 6. Genotyping of 275 in-
dividuals from 72 families for seven SNPs in the GCLM
gene showed supportive (although by no means signifi-
cant) evidence of linkage between schizophrenia and two
GCLM markers. The highest LOD score, 1.382 (corre-
sponding to ), was obtained under assumed dom-Pp .012
inant inheritance for rs2064764, which is located within
2 kb (∼0.002 cM) of rs3170633.
To test whether there is association in the presence of
linkage, we ran a family-based association statistic test
(FBAT v. 1.7.2) in NIMH families (table 7). The results
showed that there is significant evidence ( ;Zp 3.247
) to accept the alternative hypothesis of asso-Pp .0012
ciation in the presence of linkage between SNP marker
rs2301022 and the schizophrenia phenotype: allele G at
the marker appeared as significantly overtransmitted to
the affected offspring. Moreover, the P value remains sig-
nificant, experiment-wise, after correction for multiple
testing (table 7).
To define possible functional variants associated with
the disease, we estimated pairwise linkage disequilibrium
(LD) for all 17 SNPs of GCLM and GSS genes in 348 un-
affected subjects from Denmark. The resulting LD map
showed very strong association among all markers within
each of the two genes (fig. 4). Thus, any association with
this region might suggest the presence of a functional var-
iant associated with schizophrenia.
On the basis of the strong association of two SNPs
(rs2301022 and rs718875) in the 5′ region of the GCLM
gene and schizophrenia, we examined the relationship of
these variants and the GCLM expression level in the Swiss
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Table 6. Family Linkage Analysis of the
GCLM Gene
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 4. GOLD plot of pairwise LD for 17 SNPs that belong to
genes GCLM and GSS. The 17 SNPs used in association and linkage
studies and graphically presented in figure 2 are labeled on both
axes. The color differences represent regions of the local map that
are in disequilibrium and the magnitude of that disequilibrium.
Regions of high and low LD are presented in red and blue, re-
spectively. GOLD plot shows very strong LD within each gene.
Table 7. Family-Based Association Test for SNP
Markers Linked to GCLM
Marker Allele
Allele
Frequency Z P
rs2301022 G .567 3.247 .0012
rs718875 T .892 .202 .8399
rs718873 T .862 .258 .7963
rs769211 T .209 .784 .4332
rs2064764 A .428 .935 .3496
rs3170633 A .441 .577 .5637
rs2235971 A .266 .832 .4054
NOTE.—Cells highlighted in bold show significantly dif-
ferent values.
population. The mRNA steady-state level in cultured fi-
broblasts showed a significant correlation with these two
SNPs ( ). This result confirms the functional effectPp .040
of the GCLM variants on the schizophrenia phenotype.
However, it is still unknown in which way these variants
affect the GCLM gene expression, since their localization
is not directly related to any of the currently known reg-
ulatory sequences. It is worth noting that the GCLM gene
is localized on chromosome 1p21, the region shown by
previous linkage studies to be one of the several regions
critical for schizophrenia.30,31
Several genes involved in GSH metabolism have already
been considered as potential candidates for schizophrenia.
Association of the glutathione-S-transferase M 1 gene was
shown in a subgroup of patients with schizophrenia in
Japanese32 and Korean33 populations. Case-control studies
of glutathione-S-transferase P1 and glutathione peroxidase
1 showed no association.34,35
Although GCLM is not essential for survival, its inter-
action with the GCLC subunit increases, by four- to five-
fold, the catalytic efficiency of the holoenzyme.36 The
GCLM knockout (KO) mice exhibit an increased sensitiv-
ity to oxidative stress37; mouse fetal fibroblasts are 10-fold
more sensitive to an oxidative stress than are the wild type.
Similarly, we observed lower GCL activity in patients’ fi-
broblasts exposed to an oxidative stress, compared with
that in control fibroblasts.22 Thus, a GCLM defect could
lead to GCL-activity dysregulation, consistent with the
involvement of oxidative stress–induced impairment of
neuronal processes and mitochondrial function3–7 re-
ported for schizophrenia.
GCLM KO mice showed an increased feedback inhibi-
tion of GCL activity, apparently resulting in brain GSH
levels ∼40% of normal.36,37 This is strikingly similar to the
levels 52% below normal reported for patients with schizo-
phrenia.15 Thus, GCLM KO mice can be used as a model
for further studies of GSH deficit in schizophrenia.
A GCL dysregulation could lead to cellular alterations
in the surroundings of dopaminergic terminals, affecting
the synaptic contacts on dendritic spines of prefrontal cor-
tical neurons that are particularly rich in dopamine in-
nervations. Indeed, the metabolism of dopamine gener-
ates reactive oxygen species (e.g., hydrogen peroxide and
quinones), which, in GSH-deficit conditions, are not ad-
equately neutralized and, thus, induce cellular damage.11
Interestingly, in rat models, GSH deficit and excess do-
pamine during development mimic structural and func-
tional anomalies observed in patients: they exhibited a
decrease in spine density of pyramidal neurons (F.
Gheorghita, unpublished data) and, selectively, in GABA-
parvalbumin immunoreactivity of prefrontal cortex,21
similar to patients.38,39 The same rat model presented an
impairment in object recognition18,19 and in integration
ofolfactory information,40 reproducingsomecognitivedef-
icits of schizophrenia.
Furthermore, NMDA-R hypofunction is implicated in
schizophrenia, since the NMDA-R antagonist phencycli-
dine induces a psychotic syndrome.41 In the case of GSH
deficit, NMDA-R activity could be depressed through in-
teraction at their redox sites.12,13 Similarly, in rat hippo-
campal slices, GSH depletion impaired NMDA-dependent
synaptic plasticity.20
In conclusion, these studies provide converging evi-
dence of a link between schizophrenia and GCLM genetic
variations, which affect the function of the encoded pro-
tein in its ability to promote GSH synthesis when chal-
lenged by an oxidative stress. They support the new con-
cept that a dysregulation of GSH metabolism is one of the
vulnerability factors contributing to the development of
the disease.
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